A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod (LEGATO-HD)

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease

The primary objective of this study is to assess the efficacy of laquinimod as treatment in participants with HD after 52 weeks using the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS or TMS).

Study Overview

• Status: Completed
• Conditions: Huntington's Disease
• Intervention / Treatment: Drug: Placebo; Drug: Laquinimod

• Study Type: Interventional
• Enrollment (Actual): 352
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Edmonton, Canada, T6G 2G3
    • Teva Investigational Site 11124
  • British Columbia
    • Vancouver, British Columbia, Canada, V6T 2B5
      • Teva Investigational Site 11080
  • Ontario
    • Ottawa, Ontario, Canada, K1G 4G3
      • Teva Investigational Site 11118
    • Toronto, Ontario, Canada, M3B 2S7
      • Teva Investigational Site 11079
• Czechia
  • Prague, Czechia, 12800
    • Teva Investigational Site 54108
• Germany
  • Berlin, Germany, 10117
    • Teva Investigational Site 32480
  • Bochum, Germany, 44791
    • Teva Investigational Site 32482
  • Erlangen, Germany, 91054
    • Teva Investigational Site 32618
  • Munchen, Germany, 81675
    • Teva Investigational Site 32483
  • Munster, Germany, 48149
    • Teva Investigational Site 32481
  • Ulm, Germany, 89081
    • Teva Investigational Site 32479
• Italy
  • Bologna, Italy, 40139
    • Teva Investigational Site 30168
  • Milano, Italy, 20133
    • Teva Investigational Site 30098
  • Milano, Italy, 20133
    • Teva Investigational Site 30100
  • Napoli, Italy, 80131
    • Teva Investigational Site 30097
  • San Giovanni Rotondo, Italy, 71013
    • Teva Investigational Site 30099
• Netherlands
  • Leiden, Netherlands, 2333 ZA
    • Teva Investigational Site 38066
• Portugal
  • Lisboa, Portugal, 1649-035
    • Teva Investigational Site 36026
• Russian Federation
  • Kazan, Russian Federation, 420101
    • Teva Investigational Site 50379
  • Moscow, Russian Federation, 125367
    • Teva Investigational Site 50380
  • Nyznij Novgorod, Russian Federation, 603126
    • Teva Investigational Site 50381
• Spain
  • Barakaldo, Spain, 48903
    • Teva Investigational Site 31185
  • Barcelona, Spain, 8036
    • Teva Investigational Site 31097
  • Barcelona, Spain, 8041
    • Teva Investigational Site 31110
  • Burgos, Spain, 09006
    • Teva Investigational Site 31186
  • Madrid, Spain, 28034
    • Teva Investigational Site 31131
  • Sevilla, Spain, 41009
    • Teva Investigational Site 31187
• United Kingdom
  • Aberdeen, United Kingdom, AB25 2ZN
    • Teva Investigational Site 34176
  • Birmingham, United Kingdom, B15 2SG
    • Teva Investigational Site 34177
  • Liverpool, United Kingdom, L9 7LJ
    • Teva Investigational Site 34194
  • London, United Kingdom, NW1 2PG
    • Teva Investigational Site 34179
  • London, United Kingdom, SE1 9RT
    • Teva Investigational Site 34209
  • London, United Kingdom, SW17 0QT
    • Teva Investigational Site 34204
  • London, United Kingdom, W12 0NN
    • Teva Investigational Site 34203
  • Manchester, United Kingdom, M13 9WL
    • Teva Investigational Site 34175
  • Newcastle-Upon-Tyne, United Kingdom, NE6 4QD
    • Teva Investigational Site 34215
  • Sheffield, United Kingdom, S5 7AU
    • Teva Investigational Site 34216
• United States
  • California
    • La Jolla, California, United States, 92037
      • Teva Investigational Site 12566
    • Los Angeles, California, United States, 90095
      • Teva Investigational Site 12565
    • San Francisco, California, United States, 94143
      • Teva Investigational Site 12567
  • Colorado
    • Englewood, Colorado, United States, 80113
      • Teva Investigational Site 12575
  • Florida
    • Tampa, Florida, United States, 33612
      • Teva Investigational Site 13490
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Teva Investigational Site 13326
  • Kansas
    • Wichita, Kansas, United States, 67226
      • Teva Investigational Site 12568
  • Maryland
    • Baltimore, Maryland, United States, 21287-0005
      • Teva Investigational Site 12574
  • Minnesota
    • Golden Valley, Minnesota, United States, 55427
      • Teva Investigational Site 12571
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Teva Investigational Site 12572
  • New York
    • New York, New York, United States, 10032
      • Teva Investigational Site 12570
    • Rochester, New York, United States, 14618
      • Teva Investigational Site 12569
  • Tennessee
    • Memphis, Tennessee, United States, 38163
      • Teva Investigational Site 13489
    • Nashville, Tennessee, United States, 37232
      • Teva Investigational Site 13325
  • Texas
    • Houston, Texas, United States, 77030
      • Teva Investigational Site 12815
  • Washington
    • Kirkland, Washington, United States, 98034
      • Teva Investigational Site 12576

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 55 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Documentation of prior positive genetic testing for HD, or a clinical diagnosis of symptomatic HD.
• Presence of 36-49 cytosine-adenosine-guanine (CAG) repeats, inclusive, in the huntingtin gene based on centralized CAG testing during screening.
• Male or female between 21-55 years of age, inclusive, with an onset of HD at or after 18 years of age.
• Women of child-bearing potential (women who are not post menopausal or who have undergone surgical sterilization) must practice an acceptable method of birth control for 30 days before taking the study treatment, and 2 acceptable methods of birth control during all study duration and until 30 days after the last dose of treatment was administered.
• A sum of greater than (>) 5 points on the UHDRS-TMS at the screening visit.
• Able and willing to provide written informed consent prior to any study related procedure being performed at the screening visit. Participants with a legal guardian should be consented according to local requirements.
• Willing to provide a blood sample for genomic CAG analysis at the screening visit.
• Willing and able to take oral medication and able to comply with the study specific procedures.
• Ambulatory, being able to travel to the study center, and judged by the investigator as likely to be able to continue to travel for the duration of the study.
• Availability and willingness of a caregiver, informant, or family member to provide input at study visits assessing Clinician's Interview-Based Impression of Change (CIBIC)-Plus, Clinical Dementia Rating - Sum of Boxes (CDR-SB), Problem Behaviors Assessment-Short form (PBA-s) and Huntington's Disease Quality of Life (HD-QoL). A caregiver is recommended to be someone who attends to the participant at least 2 to 3 times per week for at least 3 hours per occasion, and the suitability of the caregiver should be judged by the investigator.

• For participants taking allowed antidepressant medication, the dosing of medication must have been kept constant for at least 30 days before baseline and must be kept constant during the study.

  • Additional criteria may apply, please contact the investigator for more information.

Exclusion Criteria:

• Use of immunosuppressive agents, or cytotoxic agents, including cyclophosphamide and azatioprine within 12 months prior to screening.
• Previous use of laquinimod.
• Use of moderate/strong inhibitors of cytochrome P450 (CYP)3A4 within 2 weeks prior to randomization.
• Use of inducers of CYP3A4 within 2 weeks prior to randomization.
• Pregnant or breastfeeding.

• Participants with a clinically significant or unstable medical or surgical condition that may put the participant at risk when participating in the study or may influence the results of the study or affect the participant's ability to take part in the study, as determined by medical history, physical examinations, electrocardiogram (ECG), or laboratory tests. Such conditions may include:

  • A major cardiovascular event (for example; myocardial infarction, acute coronary syndrome, de-compensated congestive heart failure, pulmonary embolism, coronary revascularization) that occurred prior to randomization.
  • Any acute pulmonary disorder.
  • A central nervous system (CNS) disorder other than HD that may jeopardize the participant's participation in the study, including such disorders that are demonstrated on the baseline MRI (based on local read).
  • A gastrointestinal disorder that may affect the absorption of study medication.
  • Acute or chronic renal disease including acute kidney injury (AKI).
  • Any form of acute or chronic liver disease.
  • Known human immunodeficiency virus (HIV) positive status. Participants will undergo an HIV test at screening per local requirements, if applicable.
  • Any malignancies, excluding basal cell carcinoma, in the 5 years prior to randomization.
• Any clinically significant, abnormal, screening laboratory result which in the opinion of the investigator, affects the participant' suitability for the study or puts the participant at risk if he/she enters the study.
• Unsuitable for MRI (for example; claustrophobia, metal implants).
• Alcohol and/or drug abuse within the 12 months prior to screening, as defined by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition Text Revision (DSM IV TR) criteria for substance abuse.
• Participants with active suicidal ideation during the past month as measured by a most severe suicide ideation score of 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan) or 5 (Active Suicidal Ideation with Specific Plan and Intent) on the baseline screening Columbia-Suicide Severity Rating Scale (C-SSRS) or participants who answer "Yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) if the attempt or acts were performed within 1 year of screening, or participants who, in the opinion of the investigator, present a serious risk of suicide.
• Participants with known intracranial neoplasms, vascular malformations, or intracranial hemorrhage.
• Known drug hypersensitivity that would preclude administration of laquinimod or placebo, such as hypersensitivity to mannitol, meglumine or sodium stearyl fumarate.
• Swallowing difficulties that would preclude administration of laquinimod or placebo capsules.
• Treatment with any investigational product within 30 days of screening or participants planning to participate in another clinical study assessing any investigational product during the study. Participants in non-interventional and/or observational studies will not be excluded from participating in this study.
• Treatment with tetrabenazine within 30 days of the study baseline visit.

• Treatment with antipsychotic medication within 30 days of the study baseline visit.

  • Additional criteria may apply, please contact the investigator for more information

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo; Participants will receive 3 capsules of matching laquinimod placebo, orally once daily for 52 weeks.	Drug: Placebo; Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
EXPERIMENTAL: Laquinimod 0.5 mg; Participants will receive 1 capsule of laquinimod 0.5 milligrams (mg) and 2 capsules of matching placebo, orally once daily for 52 weeks.	Drug: Placebo; Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.; Drug: Laquinimod; Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
EXPERIMENTAL: Laquinimod 1.0 mg; Participants will receive 2 capsule of laquinimod 0.5 mg (total 1.0 mg laquinimod) and 1 capsule of matching placebo, orally once daily for 52 weeks.	Drug: Placebo; Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.; Drug: Laquinimod; Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
EXPERIMENTAL: Laquinimod 1.5 mg; Participants will receive 3 capsules of laquinimod 0.5 mg (total 1.5 mg laquinimod), orally once daily. Note: The treatment of this high dose arm was discontinued as of 10 January 2016.	Drug: Laquinimod; Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in UHDRS-TMS at Week 52	UHDRS is a research tool developed by Huntington Disease (HD) Study Group to provide a uniform assessment of the clinical features and course of HD. Components of the full UHDRS assess motor function, cognition, behaviour, functional abilities, independence scale and total functional capacities. Motor function assessment includes TMS and Total Functional Capacity (TFC) score. The UHDRS TMS assesses all the motor features of HD and includes maximal chorea, maximal dystonia, ocular pursuit, saccade initiation and velocity, dysarthria, tongue protrusion, finger tapping, hand pronation and supination, luria, rigidity, bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these was rated on a scale of 0 (normal motor function) to 4 (severely impaired motor function). TMS score is a sum of individual scores ranging from 0 (normal motor function) to 124 (severely impaired motor function). Lower TMS scores indicate better motor function.	Baseline, Week 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change From Baseline in Caudate Volume (Brain Atrophy) at Week 52	Brain atrophy was assessed using magnetic resonance imaging (MRI) measures of caudate volume. Caudate volume atrophy is a sensitive biomarker in very early HD and correlates with disease progression. Brain atrophy in the caudate refers to the shrinkage in volume, so that a decrease in volume is a positive value, while an increase in volume is a negative value. Percent change in caudate volume at Week 52 was calculated as the change in caudate volume since the baseline visit, divided by the baseline caudate volume and multiplied by 100.	Baseline, Week 52

Collaborators and Investigators

• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Publications and helpful links

General Publications

• Ehrnhoefer DE, Caron NS, Deng Y, Qiu X, Tsang M, Hayden MR. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Exp Neurol. 2016 Sep;283(Pt A):121-8. doi: 10.1016/j.expneurol.2016.06.008. Epub 2016 Jun 11.

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 28, 2014
• Primary Completion (ACTUAL): June 19, 2018
• Study Completion (ACTUAL): June 19, 2018

Study Registration Dates

• First Submitted: August 12, 2014
• First Submitted That Met QC Criteria: August 12, 2014
• First Posted (ESTIMATE): August 13, 2014

Study Record Updates

• Last Update Posted (ACTUAL): May 4, 2020
• Last Update Submitted That Met QC Criteria: April 30, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Genetic Diseases, Inborn; Basal Ganglia Diseases; Movement Disorders; Neurodegenerative Diseases; Dyskinesias; Heredodegenerative Disorders, Nervous System; Dementia; Cognition Disorders; Chorea; Huntington Disease
• Other Study ID Numbers: TV5600-CNS-20007; 2014-000418-75 (EUDRACT_NUMBER)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No